Healthcare / Womens Health
Daré Bioscience's Ovaprene Shows Promise in Phase 3 Trial
Daré Bioscience (DARE) stock experienced a significant surge after announcing positive interim results from its Phase 3 clinical trial for Ovaprene, a novel hormone-free intravaginal contraceptive. This development has drawn considerable at...